QualityDipStocks / Health Care · Medical instruments
Stryker SYK
In a deep dip: 25% below its 52-week high.
A quality company trading near our fair value estimate.
- Fair value est.
- $291.87at the price
- Market Value
- forming
- Off 52-wk high
- −25%
- Risk vs market
- Lowbeta 0.16
4 bullish · 0 bearish See why
Key levels
Every level vs today’s $291.86
- 52-wk lowlowest close, 1 year$269.75−7.6%
- PriceFri Oct 30 close$291.86you are here
- Fair value est.base case$291.87at the price
- 52-wk highhighest close, 1 year$387.46+32.8%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 10.8% ±2 points. Bear = 10.5% and 8.8%; bull = 8.5% and 12.8% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price sits inside the range.
What the price implies To be worth today’s price, SYK’s free cash flow would need to grow about 11% a year for five years; our estimate uses 11%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much SYK moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 2.4× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.16
- Volatility
- 31% vs 13% SPY
- Correlation SPY
- 0.07
- Correlation QQQ
- −0.10
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ValuationP/E of 31.0× is 25% below its own average of 41.5× at the last 3 fiscal year-ends.
GrowthSales compounded 11% a year from FY2022 to FY2025.
ProfitabilityOperating margin of 21%, above the 13% median for the 89 Health Care companies we cover.
QualityPasses all four of our quality checks: cash generation, returns on capital, growth and balance sheet.
Top bearish points 0 of 5
Nothing in our data makes a clear bear case right now.
Who’s talking about it
Notable investors, executives, analysts and public figures on Stryker in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Medical instruments
All fundamentals
P/E 31.0 · FCF yield 4.1% · Sales +8%
Valuation
- P/E
- 31.0×3-yr-end avg 41.5× · Health Care median 29.2×
- Price / FCF
- 24.6×
- FCF yield
- 4.1%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 4.27×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $112Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $26.3B
- Sales growth, 12 months
- +7.9%vs the 12 months before
- Sales growth, 3 yrs
- +10.8%/yrfrom FY2022
- Diluted EPS, 12 months
- $9.39
- EPS growth, last FY
- +8.2%
- Net income, 12 months
- $3.6B
- Net income growth
- +23%12 months vs before
Profitability
- Gross margin
- 65.3%
- Operating margin
- 20.7%
- Net margin
- 13.8%
- FCF margin
- 17.4%
- Return on equity
- n/anot reported in its SEC filings
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- n/anot reported in its SEC filings
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- 9.3×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $4.6B
- FCF growth, 12 months
- +12%
- Dividend yield
- 1.19%$1.3B paid
- Payout ratio
- 37%
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- −0.5%diluted shares vs a year ago
- Stock-based comp
- $256M
Trailing 12 months to Sep 30, 2026. From Stryker’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $291.87 · FCF value $286.74
Assumes 10.8% growth for 5 years (revenue grew 10.8% a year FY22–FY25), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $11.89 a share (trailing 12 months to Sep 30, 2026), from the 10-Q filed Oct 30, 2026. Net debt $11.2B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. We watch it daily for our three reversal signal rules while it sits in a dip.
Momentum & 52-week range
RSI 48 · 5 days −5.0%
The business
FCF $4.7B · Sales +9%
- Free cash flow, 12 months$4.7B
- Free-cash-flow yield3.9%
- Free-cash-flow margin18%
- Gross margin65%
- Operating margin22%
- Return on invested capital11%
- Return on equity17%
- Sales growth (latest quarter vs year-ago quarter)+9%
- Net debt / EBITDA1.7×
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
Get a text when SYK fires a reversal signal
One text when a published rule fires on SYK or any of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.